Down-regulation of Intrinsic P-glycoprotein Expression in Multicellular Prostate Tumor Spheroids by Reactive Oxygen Species*

Maria WartenbergDagger , Frederike C. LingDagger , Maurice SchallenbergDagger , Anselm T. Bäumer§, Kerstin PetratDagger , Jürgen HeschelerDagger , and Heinrich SauerDagger

From the Dagger  Department of Neurophysiology and the § Department III for Internal Medicine, University of Cologne, D-50931 Cologne, Germany

Received for publication, January 8, 2000, and in revised form, February 16, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Intrinsic expression of the multidrug resistance (MDR) transporter P-glycoprotein (Pgp) may be regulated by reactive oxygen species (ROS). A transient expression of Pgp was observed during the growth of multicellular tumor spheroids. Maximum Pgp expression occurred in tumor spheroids with a high percentage of quiescent, Ki-67-negative cells, elevated glutathione levels, increased expression of the cyclin-dependent kinase inhibitors p27Kip1 and p21WAF-1 as well as reduced ROS levels and minor activity of the mitogen-activated kinase (MAPK) members c-Jun amino-terminal kinase (JNK), extracellular signal-regulated kinase ERK1,2, and p38 MAPK. Raising intracellular ROS by depletion of glutathione with buthionine sulfoximine (BSO) or glutamine starvation resulted in down-regulation of Pgp and p27Kip1, whereas ERK1,2 and JNK were activated. Down-regulation of Pgp was furthermore observed with low concentrations of hydrogen peroxide and epidermal growth factor, indicating that ROS may regulate Pgp expression. The down-regulation of Pgp following BSO treatment was abolished by agents interfering with receptor tyrosine kinase signaling pathways, i.e. the protein kinase C inhibitors bisindolylmaleimide I (BIM-1) and Ro-31-8220, the p21ras farnesyl protein transferase inhibitor III, the c-Raf inhibitor ZM 336372 and PD98059, which inhibits ERK1,2 activation. ROS involved as second messengers in receptor tyrosine kinase signaling pathways may act as negative regulators of Pgp expression.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The treatment of cancer is limited by either intrinsic or acquired expression of multidrug resistance transporters, including Pgp.1 The Pgp-mediated MDR phenotype is generally characterized by a decreased cellular drug accumulation owing to an enhanced drug efflux and is caused by the overexpression of the drug transporter (1-3). Most in vitro studies have been performed using cell cultures selected for drug resistance by repetitive treatment with anti-cancer agents or using recurrent tumors from patients after chemotherapy (3). However, there is increasing evidence that Pgp-mediated MDR is likewise developing in the multicellular context of tumor tissues, without previous treatment with anti-cancer agents (4-8). This intrinsic Pgp-mediated MDR may represent a so far underestimated common in vivo situation, which may even worsen the efficacy of chemotherapeutic regimen. Especially, renal and prostate cancers are known as intrinsic drug-resistant cancers, which already have a relatively resistant phenotype to anti-cancer agents even without drug selection (9). This may explain the low response of hormone-insensitive prostate tumors toward cytostatic agents (9, 10).

In most strategies developed to reverse the MDR phenotype, chemical-reversing agents are applied, which have in common the ability to reverse the MDR phenotype through the binding to the MDR transporters (11). A more efficient strategy to circumvent MDR would be to down-regulate the expression of genes coding for the transporters. This, however, requires knowledge of the molecular mechanisms and signal transduction pathways that are involved in the regulation of MDR-related genes and elaboration of sophisticated experimental approaches that efficiently down-regulate the drug transporters. Recently, it has been pointed out that the expression of Pgp may be redox-regulated, because down-regulation of Pgp and reversal of the MDR phenotype was achieved by treatment of tumor cells with tumor necrosis factor alpha  (12), which is known to utilize low levels of ROS in its signal transduction pathway (13). On the other hand, it has been reported that high levels of ROS resulting in severe cellular oxidative stress increased the expression of the MRP-1 (14) and MDR-1b (15) genes.

In previous studies we have reported on an intrinsic Pgp MDR, which develops in quiescent cell areas of large, non-necrotic multicellular prostate tumor spheroids derived from the androgen-independent cell line DU-145 (7, 8). We furthermore demonstrated that the MDR phenotype could be reversed and that Pgp could be down-regulated upon incubation of spheroids with chemical agents that raised intracellular ROS and stimulated cell cycle activity (16). The current study presents evidence that the development of intrinsic Pgp expression is a general phenomenon occurring in multicellular tumor spheroids of different origin, i.e. melanoma, hepatoma, and glioma tumor spheroids. It is hypothesized that endogenously generated ROS are regulating the expression of intrinsic Pgp in multicellular tumor spheroids, because small, exponentially growing spheroids, which robustly generate ROS, display reduced Pgp levels, whereas up-regulation of Pgp in large, non-necrotic tumor spheroids coincides with decreased ROS levels. It is shown that an elevation of intracellular ROS is down-regulating Pgp expression via the activation of receptor tyrosine kinase signaling pathways, which results in the phosphorylation of MAPK members and mitogenic stimulation. The modulation of the intracellular redox state by BSO or other ROS-generating agents is apparently suitable in vitro to circumvent the MDR phenotype and may be useful in vivo to promote the efficacy of chemotherapeutic regimen in anti-cancer treatment.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Culture Technique of Multicellular Tumor Spheroids-- The human prostate cancer cell line DU-145 and the melanoma cell line IGR were grown in 5% CO2/humidified air at 37 °C with Ham's F-10 medium (Life Technologies, Inc., Gaithersburg, MD). The glioma cell line Gli36 and the hepatoma cell line Hepa1 were grown in Dulbecco's modified Eagle's medium (Life Technologies, Inc.). The cell culture media were supplemented with 10% fetal calf serum (Roche Molecular Biochemicals, Mannheim, Germany), 2 mM glutamine, 0.1 mM beta -mercaptoethanol, 2 mM minimal essential amino acids, 100 IU/ml penicillin, and 100 µg/ml streptomycin (ICN Flow, Meckenheim, Germany). Spheroids were grown from single cells. Cell monolayers were enzymatically dissociated with 0.2% trypsin, 0.05% EDTA (ICN Flow) and seeded in siliconized 250-ml spinner flasks (Integra Biosciences, Fernwald, Germany) with 250 ml of complete medium and agitated at 20 rpm using a Cell Spin stirrer system (Integra Biosciences). Cell culture medium was partially (125 ml) changed every day.

Incubation with BSO, Glutamine-reduced Medium, and Ebselen-- For incubation with BSO and glutamine-reduced medium, small multicellular tumor spheroids (diameter 130 ± 50 µm, day 5) were transferred to bacteriological tissue culture plates (diameter 10 cm) (Becton Dickinson, Meylan, France) filled with 10 ml of F10 cell culture medium. They were subsequently treated for 7 days with 50 µM BSO (Sigma, Deisenhofen, Germany), which was added to the cell culture medium. For incubation in glutamine-reduced medium, F10 cell culture medium was supplemented with 10% fetal calf serum, 0.1 mM beta -mercaptoethanol, 2 mM minimal essential amino acids, 100 IU/ml penicillin, and 100 µg/ml streptomycin, whereas glutamine was omitted as an additive. Tumor spheroids were cultivated for 7 days in the glutamine-reduced medium. The cell culture medium was changed every 24 h. Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) (Sigma) was dissolved in Me2SO and was used at a final concentration of 1 µM.

Incubation with EGF and Inhibitors of the Tyrosine Kinase Signaling Pathway-- EGF was purchased from Calbiochem (San Diego, CA). Large, non-necrotic tumor spheroids (diameter 300 ± 50 µm, day 14) were removed from spinner flasks and were incubated for 24 h in 6-cm bacteriological Petri dishes with EGF in a concentration of 2.5, 5, 20, and 50 ng/ml. Subsequently, they were fixed and Pgp expression was investigated by immunohistochemistry. Inhibitors of the receptor tyrosine kinase pathway were purchased from Calbiochem. Tumor spheroids were incubated with the EGF receptor kinase inhibitor tyrphostin AG 1478 (10 µM), the farnesyltransferase inhibitor (E,E)-(2-oxo-2-{[(3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy]amino}ethyl)phosphonic acid, (2,2-dimethyl-1-oxo-propoxyl)methyl ester (FPT inhibitor III) (1 µM), the c-Raf inhibitor N-[5-(3-dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide (ZM 336372) (1 µM), the PKC inhibitors bisindolylmaleimide I (BIM-1) (1 µM) and bisindolylmaleimide IX (Ro-31-8220) (0.5 µM), and the MAPK kinase inhibitor 2'amino-3'-methoxyflavone (PD98059) (20 µM) for 24 h. Subsequently, the tumor spheroids were fixed and anti-Pgp immunohistochemistry was performed.

Incubation with H2O2 and Lethal Cell Staining-- Incubation with H2O2 was performed with 6-day-old tumor spheroids. Spheroids were incubated for 24 h in 6-cm bacteriological Petri dishes containing 10 ml of F10 cell culture medium supplemented with either 1, 200, 500, or 750 µM H2O2. After the incubation time tumor, spheroids were either fixed for immunohistochemistry or the incubation medium was exchanged for F10 medium supplemented with 1 µM SYTOX green (Molecular Probes; Eugene, OR), which intensively stains the nuclei of cells with compromised cell membranes. Following 1 h of incubation, the percentage of labeled lethal cells was assessed using the 488-nm band of the argon laser of the confocal setup and a long-pass LP 515-nm filter set.

Doxorubicin Fluorescence Recording and Confocal Laser Scanning Microscopy-- The fluorescent cytostatic anti-cancer agent doxorubicin (Sigma Chemical Co.) (excitation at 543 nm, emission, long-pass filter LP 570 nm) was used at a concentration of 10 µM unless otherwise indicated. Multicellular tumor spheroids were loaded with doxorubicin at 37 °C for 90 min. After recording of doxorubicin fluorescence by confocal laser scanning microscopy, spheroids were transferred to doxorubicin-free cell culture medium and incubated at 37 °C for 30 min. Following this incubation doxorubicin retention in multicellular spheroids was evaluated.

Fluorescence recordings were performed by means of a confocal laser scanning setup (LSM 410, Carl Zeiss, Jena, Germany), connected to an inverted microscope (Axiovert 135, Carl Zeiss). Fluorophores were excited using a 0.5-milliwatt helium-neon laser (single excitation at 543 nm). A 25×, numerical aperture 0.8, oil immersion-corrected objective (Carl Zeiss) was applied. Doxorubicin fluorescence was measured in 3600-µm2 areas in a depth up to 80 µm from the spheroid periphery.

Immunohistochemical Techniques and Quantitative Immunohistochemistry-- Antibody staining was performed on whole mount multicellular spheroids. The monoclonal anti-p27Kip1 and p21WAF-1 antibodies were obtained from PharMingen (Hamburg, Germany) and were used in a concentration of 2.5 µg/ml. The monoclonal antibodies directed against the NADPH oxidase subunits p47phox and p67phox (Dianova Hamburg, Germany) were used in a concentration of 5 µg/ml. The polyclonal anti-mdr (Ab-1) antibody (Oncogene Research Products, Cambridge, UK) was used in a concentration of 5 µg/ml. The anti-active MAPK polyclonal antibody directed against ERK1,2 (dilution 1:20), the anti-active JNK (dilution 1:20), and the anti-active p38 MAPK (dilution 1:20) polyclonal antibodies were obtained from New England BioLabs (Beverly, MA). The monoclonal anti-proliferating cell protein Ki-67 antibody was obtained from Sigma and used in a concentration of 7.5 µg/ml. Spheroids were washed in phosphate-buffered saline (PBS), fixed in either ice-cold methanol/acetone (7:3) or 4% paraformaldehyde (4 °C) and permeabilized in PBS supplemented with 1% Triton X-100 (PBST) (Sigma). Subsequently, they were incubated for 1 h in PBST 0.01% containing 10% fat-free milk powder to reduce nonspecific binding and for further 2 h with primary antibody. After washing three times in PBST (0.1%), the spheroids were incubated for 60 min in PBST (0.01%) supplemented with 10% milk powder and either a Cy5-conjugated F(ab')2 fragment goat anti-mouse IgG (H+L) (concentration 3.25 µg/ml), a Cy5-conjugated F(ab')2 fragment goat anti-rabbit IgG (H+L) (concentration 4.6 µg/ml), or a Cy5-conjugated F(ab')2 fragment goat anti-rat (concentration 4.6 µg/ml) (all from Dianova, Hamburg, Germany). Excitation was performed using a 633-nm helium-neon laser of the confocal setup. Emission was recorded using a long-pass LP 655-nm filter set.

For quantitative immunohistochemistry, confocal images were recorded from whole mount multicellular spheroids stained with only secondary antibodies (background fluorescence image) and spheroids stained with primary and secondary antibodies. The pinhole settings of the confocal setup were adjusted to yield optical slices of 10-µm thickness. After subtraction of background fluorescence, the fluorescence signal (counts) was evaluated by the image analysis software of the confocal setup in 3600-µm2 areas of interest and was routinely exported for further analysis to the Sigma Plot graphic software.

Determination of the Intracellular Redox Levels-- Intracellular redox levels were measured using the fluorescent dye 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) (Molecular Probes), which is a nonpolar compound that is converted into a non-fluorescent polar derivative (H2DCF) by cellular esterases after incorporation into cells. H2DCF is membrane-impermeable and is rapidly oxidized to the highly fluorescent 2',7'-dichlorofluorescein (DCF) in the presence of intracellular ROS (17). For the experiments, multicellular tumor spheroids were incubated in E1 medium containing (in millimolar) NaCl 135, KCl 5.4, CaCl2 1.8, MgCl2 1, glucose 10, HEPES 10 (pH 7.4 at 23 °C), and 20 µM H2DCFDA dissolved in dimethyl sulfoxide (Me2SO) was added. After 5, 10, 15, 20, and 30 min intracellular DCF fluorescence (corrected for background fluorescence) was evaluated in 3600-µm2 regions of interest using an overlay mask. For fluorescence excitation, the 488-nm band of the argon ion laser of the confocal setup was used. Emission was recorded using a long-pass LP515-nm filter set.

Determination of Intracellular Glutathione-- Glutathione levels were determined using a commercially available glutathione assay kit (Calbiochem). Tumor spheroids were enzymatically dissociated in 0.1% trypsin/0.05% EDTA. An aliquot of 3.5 × 106 cells was lysed in 0.5 ml of meta-phosphoric acid, freeze-thawed, and centrifuged (3000 × g) for 10 min. 50 µl of the supernatant was used for the assay. The substitution product obtained with reduced glutathione was transformed under alkaline conditions into a chromophoric thione with a maximal absorbance at 400 nm. The absorbance of the samples was determined using a Dynex (Reutlingen, Germany) microplate reader.

Reverse Transcriptase-Polymerase Chain Reaction (RT- PCR)-- MDR-1 gene expression was monitored by RT-PCR. After the indicated growth times for tumor spheroids, culture medium was aspirated and spheroids were washed in PBS. Subsequently the cells were lysed with 1 ml of RNA-clean (PqLab, Erlangen, Germany) and processed according to the manufacturer's protocol to obtain total cellular RNA. 1-µg aliquots were electrophoresed through 1.2% agarose-0.67% formaldehyde gels and stained with ethidium bromide to verify the quantity and quality of the RNA. 1 µg of the isolated total RNA was reverse-transcribed using random primers and Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) for 60 min at 42 °C and 10 min at 70 °C. The single-stranded cDNA was amplified by polymerase chain reaction using Taq DNA polymerase (Sigma). 35 cycles were performed under the following conditions: 20 s, 94 °C; 30 s, 60 °C; 60 s, 72 °C. The sequence for hMDR-1 sense and antisense primers were 5'-CCCATCATTGCAATAGCAGG-3' and 5'-GTTCAAACTTCTGCTCCTGA-3' (18). PCR amplification gave a single 167-base pairs (bp) fragment originated from hMDR-1 mRNA. For semi-quantification, PCR conditions were chosen so that the reaction was within the linear exponential phase with respect to the amount of cDNA template and number of cycles performed. Equal amounts of RT-PCR products were loaded on 1.5% agarose gels, and optical densities of ethidium-bromide-stained DNA bands were quantified.

Immunoblotting-- Multicellular spheroids were lysed in 125 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerine, 20 mM dithiothreitol, 1 mM EDTA, 0.01% bromphenol blue. Equal amounts of proteins (15 µg per lane) were electrophoresed on 10% SDS-polyacrylamide gel electrophoresis gels. Immunoblots of Pgp were prepared by electrophoretic transfer of proteins from SDS-polyacrylamide gels to nitrocellulose by semi-dry Western blotting. The nitrocellulose transfers were incubated for 1 h in blocking buffer (5% low-fat milk powder in PBS containing 0.1% Tween 20) and then probed for 1 h with 5 µg/ml polyclonal rabbit anti-mdr antibody (Ab-1) (Oncogene) in PBS, 0.1% Tween 20. As secondary antibodies, a horseradish peroxidase-conjugated goat anti-rabbit (dilution 1:2 × 104) antibody (Dianova) was used.

Statistical Analysis-- Data are given as mean values ± S.D., with n denoting the number of experiments. In each experiment at least 20 multicellular spheroids were analyzed. Student's t test for unpaired data was applied as appropriate. A value of p < 0.05 was considered significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transient Expression of Pgp in Multicellular Tumor Spheroids-- We have previously reported on the development of an intrinsic Pgp-mediated MDR in multicellular prostate tumor spheroids of the DU-145 cell line, which paralleled the induction of cell quiescence in the depth of the multicellular tissue (7, 8). To evaluate whether the transient expression of Pgp observed in DU-145 tumor spheroids represents a general phenomenon of multicellular neoplastic tissues, tumor spheroids of different origin, i.e. melanoma tumor spheroids of the IGR cell line, hepatoma spheroids of the Hepa1 cell line, and glioma spheroids of the Gli36 cell line were screened for the expression of Pgp and compared with protein levels of Pgp in tumor spheroids of the DU-145 cell line. It was observed that all cell lines under investigation transiently expressed Pgp (Fig. 1, A-D) (n = 3). Owing to the cell-specific growth kinetics of tumor spheroids of different origin (Fig. 2) the maximum Pgp expression occurred at different times in DU-145, IGR, Hepa1, and Gli36 tumor spheroids (n = 3). In DU-145 prostate tumor spheroids the expression of the MDR-1 gene in relation to tumor spheroid age was evaluated by RT-PCR and immunoblot analysis (Fig. 3). It was evidenced that MDR-1 expression paralleled Pgp expression, i.e. it was low in small tumor spheroids and increased with the development of quiescent cell areas in 5- to 10-day-old tumor spheroids. MDR-1 expression was decreased in large tumor spheroids, which have been previously shown to contain central necrosis (27-day-old) (n = 3) (19).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Expression of intrinsic Pgp during the growth of multicellular tumor spheroids of different origin. A, multicellular DU-145 prostate tumor spheroids; B, multicellular IGR melanoma tumor spheroids; C, multicellular Gli36 glioma tumor spheroids; and D, multicellular Hepa1 tumor spheroids. The data were fitted by a Gaussian algorithm.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Growth kinetics of multicellular tumor spheroids of different origin. The investigated tumor spheroids were: glioma tumor spheroids of the Gli36 cell line, melanoma tumor spheroids of the IGR cell line, prostate tumor spheroids of the DU-145 cell line, and hepatoma tumor spheroids of the Hepa1 cell line.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   Pgp expression and MDR-1 gene expression in respect to the cultivation time of multicellular DU-145 tumor spheroids. A, immunohistochemical analysis of Pgp expression in (from left to right) whole mount small (diameter 100 ± 50 µm, days 3-6 of tumor spheroid culture), large non-necrotic (diameter 300 ± 50 µm, days 10-15 of tumor spheroid culture), as well as in large tumor spheroids containing central necrosis (diameter 500 ± 100 µm, days 18-40 of tumor spheroid culture). The bar represents 50 µm. B, immunoblot analysis of Pgp expression in 1-, 5-, 11-, 16-, and 36-day-old tumor spheroids. Pgp expression obtained from the gel was analyzed by densitometric analysis. Shown is a representative of three independent experiments, which yielded comparable results. C, RT-PCR analysis of MDR-1 gene expression in respect to the cultivation time of multicellular tumor spheroids. After different times of cultivation, as indicated, RNA was prepared from tumor spheroids and the MDR-1-specific (167-bp) PCR products were amplified and analyzed by gel electrophoresis, as described under "Experimental Procedures." MDR-1 mRNA expression obtained from the gel was analyzed by densitometric analysis. Shown is a representative of three independent experiments which yielded comparable results.

To correlate the increased expression of Pgp in DU-145 tumor spheroids with the proliferation status of the tumor cells, the tissue levels of the CDK inhibitors p27Kip1 and p21WAF-1 as well as the expression of the proliferation-associated antigen Ki-67 were analyzed. It was observed that p27Kip1 (Fig. 4A) and p21WAF-1 (Fig. 4B) were up-regulated in parallel to Pgp with increasing size of tumor spheroids (n = 3). With the onset of central necrosis, which occurs at a critical size of 350 ± 50 µm in DU-145 tumor spheroids (20) p27Kip1 expression declined to the level observed in small tumor spheroids, whereas p21WAF-1 expression remained on an elevated level. Ki-67 expression was inversely correlated to the expression of Pgp and declined with increasing age and size of tumor spheroids, indicating a decrease in proliferative activity (n = 3).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   Expression of p27Kip1 (A), p21WAF-1 (B), and Ki-67 (C) in DU-145 multicellular tumor spheroids after different times of cell culture. Elevated expression of p27Kip1 and p21WAF-1 was observed in large, non-necrotic tumor spheroids. In large tumor spheroids containing central necrosis a decline of p27Kip1 was detected, whereas the expression of p21WAF-1 remained on an elevated level. Ki-67 expression declined with increasing tumor spheroid age. The data are presented as positive nuclei per 3600 µm2. Size classes of tumor spheroids are indicated by dashed vertical lines.

The apparent correlation of cell quiescence and increased Pgp expression was furthermore corroborated by investigation of the intrinsic activity of the MAPK members ERK1,2, JNK, and p38 MAPK, which are involved in mitogenic and stress-activated signaling pathways (Fig. 5). As expected, the activity of all investigated MAPK members was low in large, non-necrotic DU-145 tumor spheroids (diameter 300 ± 50 µm, days 14-15 of tumor spheroid culture), which expressed maximum levels of Pgp (see Fig. 1). Increased JNK activity was observed in small tumor spheroids (diameter 100 ± 50 µm, days 3-6 of tumor spheroid culture), as well as large tumor spheroids containing central necrosis (diameter 500 ± 100 µm, days 18-40 of tumor spheroid culture) (n = 3), whereas increased ERK1,2 activity was observed solely in exponentially growing small tumor spheroids. A low basal activity of p38 MAPK was observed in all size classes of tumor spheroids under investigation (n = 3).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   Endogenous MAPK activity in DU-145 tumor spheroids of different size classes. Phosphorylated JNK, ERK1,2, and p38 were evaluated by immunohistochemistry. The immunofluorescence of JNK in large, non-necrotic spheroids was set to 100%. Note that MAPK activity was low in large, non-necrotic tumor spheroids, which contain extended areas of cell cycle-inactive, quiescent cells. JNK activity is resumed in large multicellular tumor spheroids containing extended central necrosis correlating to an increased fraction of proliferating cells in this size class of tumor spheroids. *, p < 0.05, significantly different from MAPK activity in small spheroids.

Endogenous ROS Generation and Glutathione Content in Multicellular Tumor Spheroids-- Cancer cells endogenously generate ROS (21), which are involved in signaling pathways maintaining cell proliferation (22-24). Hence, it is expected that endogenous ROS generation is high in small tumor spheroids consisting predominantly of proliferating cells, whereas it is low in large, non-necrotic, tumor spheroids, which contain extended areas of cell cycle-inactive, quiescent cells. To determine ROS generation in multicellular DU-145 tumor spheroids, small, large non-necrotic as well as tumor spheroids containing extended central necrosis were stained with the redox-sensitive dye H2DCFDA, and the time course of ROS generation was monitored. Indeed our data show that the generation of ROS (evaluated after an incubation time of 20 min with H2DCFDA) was most pronounced in small spheroids with 280 ± 25% of the fluorescence increase observed in large, non-necrotic tumor spheroids (set to 100%) (n = 3). In tumor spheroids containing central necrosis, the ROS generation was significantly resumed and amounted to 200 ± 25% of the ROS generation observed in large, non-necrotic spheroids (n = 3) (Fig. 6A).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   Characterization of the intracellular redox state in multicellular DU-145 tumor spheroids. A, intracellular ROS levels as determined by quantification of intracellular DCF fluorescence. Small tumor spheroids (diameter 100 ± 50 µm, days 3-6 of tumor spheroid culture) (filled circles), large non-necrotic tumor spheroids (diameter 300 ± 50 µm, days 10-15 of tumor spheroid culture) (filled squares), as well as large tumor spheroids containing central necrosis (diameter 500 ± 100 µm, days 18-40 of tumor spheroid culture) (filled triangles) were incubated with the ROS indicator H2DCFDA, and the time course of the generation of fluorescent DCF was monitored. The data were fitted by linear regression. B, expression of the NADPH oxidase subunits p47phox and p67phox during cell culture of DU-145 tumor spheroids. The data were obtained by quantification of p47phox and p67phox immunofluorescence. C, evaluation of the glutathione content in DU-145 tumor spheroids after different times of cell culture. Note that the glutathione content is elevated in large non-necrotic tumor spheroids (days 7-12). The data were fitted by a Gaussian algorithm.

Intracellular ROS in DU-145 are presumably generated via an NADPH-oxidase-like enzyme, which may be differently expressed during the growth of tumor spheroids. Therefore, tumor spheroids were immunostained for the NADPH-oxidase subunits p47phox and p67phox. It was demonstrated that small tumor spheroids exerted high levels of NADPH-oxidase expression, whereas in large non-necrotic tumor spheroids a significant down-regulation of NADPH oxidase expression was observed (Fig. 6B). In large tumor spheroids containing central necrosis, p47phox and p67phox expression was partially resumed which, however, did not reach statistical significance (n = 3).

Intracellular ROS levels are counterbalanced by the anti-oxidative defense system. Therefore, the intracellular content of glutathione which is an important cellular anti-oxidative thiol, was determined in tumor spheroids after different times of tumor spheroid culture (Fig. 6C). Our data demonstrate that the glutathione content was inversely correlated to ROS levels in tumor spheroids. Low levels of glutathione were determined in small tumor spheroids (6.75 ± 0.09 mM on day 3 of cell culture, n = 3), which generated ROS to significant amounts. However, elevated glutathione levels were found in large, non-necrotic tumor spheroids with a maximum at day 12 of tumor spheroid cell culture (11 ± 0.85 mM, n = 3) corresponding to spheroid diameters of ~250 µm. This size class of tumor spheroids consequently generated low levels of ROS (see Fig. 6A). Prolonged culture times (>12 days) resulted in a decline of the glutathione content, which is in line with the observed elevated ROS levels in large tumor spheroids containing extended central necrosis.

Effects of Intracellular ROS Elevation on Pgp Expression in Multicellular Tumor Spheroids-- The working hypothesis of our present study is based on the assumption that the intracellular redox state of tumor spheroids regulates the expression of the MDR transporter Pgp. To address this issue, intracellular glutathione was reduced either by treatment of small tumor spheroids for 7 days, i.e. from day 5 to day 12 of cell culture with 50 µM BSO, which is an irreversible inhibitor of gamma -glutamylcysteine synthetase, the rate-limiting enzyme in glutathione biosynthesis (25) or by incubating tumor spheroids in glutamine-reduced cell culture medium (26). Both experimental conditions significantly increased ROS levels as compared with untreated control spheroids (Fig. 7) (n = 3) and significantly stimulated tumor spheroid growth (data not shown). The increased ROS levels could be completely inhibited by addition of ebselen, which is an effective free radical scavenger (27). Elevation of intracellular ROS in large, non-necrotic multicellular spheroids by BSO and glutamine-reduced medium resulted in a significant down-regulation of Pgp (Fig. 8A) from 405 ± 92% to 183 ± 31% and 194 ± 42%, respectively (n = 3). The effects of intracellular elevation of ROS on the MDR phenotype were evaluated by doxorubicin retention experiments. It was observed that incubation of tumor spheroids with BSO and in glutamine-reduced medium resulted in a significant increase in doxorubicin retention from 63 ± 1% to 94 ± 1.5% and 92 ± 6%, respectively (n = 3) (Fig. 8B). The modulatory effects of elevated ROS on the levels of Pgp and on doxorubicin retention could be efficiently reversed when 1 µM of the free radical scavenger ebselen was coadministered, indicating that the observed down-regulation of Pgp by glutathione depletion was related to an increase of the intracellular redox state.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of decreased intracellular glutathione levels in large, non-necrotic tumor spheroids on the intracellular ROS level. Treatment of tumor spheroids for 7 days (i.e. from days 5 to 12) either with 50 µM BSO (A) or incubation in glutamine-reduced medium (B) significantly raised intracellular ROS as determined by the evaluation of H2DCF oxidation to fluorescent DCF. The increase in the oxidation kinetics was efficiently inhibited in the presence of the free radical scavenger ebselen (1 µM). The data were fitted by linear regression.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of decreased intracellular glutathione levels on the expression of Pgp (A) and doxorubicin retention (B) in large, non-necrotic tumor spheroids. Treatment of tumor spheroids for 7 days (days 5-12) either with 50 µM BSO or incubation in glutamine-reduced medium significantly reduced Pgp. The data represent the relative Pgp expression (%) on day 12 of cell culture in relation to the Pgp expression in tumor spheroids on day 5 of cell culture (see Fig. 1). The decrease in Pgp consequently resulted in augmented doxorubicin retention. The observed effects could be efficiently reversed by coadministration of the free radical scavenger ebselen. *, p < 0.05, significantly different from the untreated control.

Redox-regulation of Pgp may be dose-dependent. To evaluate the effects of increasing ROS concentrations on the expression levels of Pgp, 6-day-old tumor spheroids displaying intermediate Pgp levels were incubated in cell culture media containing increasing concentrations of H2O2 ranging from 1 to 750 µM. In parallel experiments cell lethality was assessed by staining dead cells with the cell death marker SYTOX green. Concentrations of 1 µM (n = 3) and 200 µM (n = 3) H2O2 significantly down-regulated Pgp expression to 128 ± 9% and 126 ± 18%, respectively, whereas Pgp expression was significantly increased to 285 ± 22%, when 750 µM H2O2 was administered (Fig. 9A). However, under these conditions cell lethality was significantly augmented (Fig. 9B), indicating that severe oxidative stress results in up-regulation of Pgp, whereas nontoxic low levels of ROS induced down-regulation of Pgp and reversal of the MDR phenotype.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of increasing concentrations of H2O2 on the expression of Pgp (A) and cell lethality (B). Six-day-old tumor spheroids were treated for 24 h with either 1, 200, 500, or 750 µM H2O2. Pgp expression was evaluated by quantitative immunohistochemisty in whole mount tumor spheroids. Cell lethality was determined by analyzing lethal SYTOX green-positive cell nuclei. Note that Pgp expression was down-regulated upon treatment with non-toxic concentrations of H2O2, whereas under conditions of increased cell lethality an up-regulation of Pgp was observed. *, p < 0.05, significantly different from the untreated control.

Effects of Intracellular ROS Elevation on p27Kip1 Levels as Well as ERK1,2 and JNK Activity-- H2O2 is known as a mediator of cell cycle activity in multicellular tumor spheroids of the DU-145 cell line (28, 29). The observed changes in the expression of Pgp may therefore be related to cell cycle stimulation. To address this issue, large non-necrotic tumor spheroids were either incubated with BSO or glutamine-reduced culture medium and the expression of either p27Kip1 (Fig. 10A) or the activity of ERK1,2 (Fig. 10B) and JNK (Fig. 10C) was assessed. Our data clearly indicate that elevation of intracellular ROS by BSO resulted in a significant down-regulation of p27Kip1 from 383 ± 90% to 70 ± 50% (n = 3). Comparable results were achieved following incubation with glutamine-reduced medium (data not shown). Consequently, BSO treatment resulted in an increase in phosphorylated ERK1,2 and JNK from 100 ± 25% to 200 ± 25% and 184 ± 46%, respectively (n = 3). The observed effects were efficiently inhibited in the presence of 1 µM ebselen. Hence, our data support the notion that ROS-mediated down-regulation of Pgp is accompanied by a stimulation of ERK1,2 and JNK pathways.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 10.   Effects of decreased intracellular glutathione levels on the expression of p27Kip1 (A), ERK1,2 (B), and JNK (C) in large, non-necrotic tumor spheroids. Treatment of tumor spheroids for 7 days (days 5-12) with 50 µM BSO reduced expression of p27Kip1 and increased expression of ERK1,2 and JNK, which is both indicative for an induction of cell cycle activity. The observed effects could be efficiently reversed by coadministration of the free radical scavenger ebselen (1 µM). *, p < 0.05, significantly different from the untreated control.

Involvement of Receptor Tyrosine Kinase-mediated Signaling Pathways in the Regulation of Pgp Expression-- The data of the present study suggest that the expression of Pgp is associated with cell quiescence and can be down-regulated by mitogenic stimulation of tumor spheroids with low levels of ROS. Furthermore, it has been recently shown that hydrogen peroxide can activate signaling pathways utilized by ROS-generating growth factors (30). We therefore hypothesized that: 1) mitogenic stimulation by the use of EGF, which has previously been shown to generate intracellular ROS (31), should likewise down-regulate Pgp, 2) the down-regulation of Pgp expression by BSO resulted from an activation of EGF-mediated signal transduction pathways (Fig. 11). To verify these assumptions large, non-necrotic tumor spheroids were either treated with tyrphostin AG 1478 (10 µM), which selectively inhibits EGF receptor kinase, or incubated for 24 h in serum-free medium and in serum-free medium supplemented with EGF in a concentration range of 2.5-50 ng/ml. The serum-free conditions were chosen to avoid a possible influence of EGF present in the fetal calf serum of the cell culture medium on the outcome of the experiments. Tyrphostin AG 1478 treatment as well as incubation in serum-free medium resulted in a significant up-regulation of Pgp as compared with control conditions. Upon treatment with 2.5, 5, 20, and 50 ng/ml EGF a dose-dependent down-regulation of Pgp to 70 ± 15%, 61 ± 19%, 34 ± 7%, and 55 ± 10%, respectively, was observed as compared with serum-free conditions (set to 100%) (n = 3) (Fig. 11A). Coadministration of 20 ng/ml EGF and the free radical scavenger ebselen (1 µM) totally abolished the down-regulation of Pgp observed by treatment with EGF alone, indicating that the down-regulation of Pgp was mediated via ROS. In a parallel set of experiments tumor spheroids were treated with BSO in the presence of specific antagonists of the EGF signaling pathway, i.e. the PKC inhibitors BIM-1 (1 µM) and Ro-31-8220 (0.5 µM), the Ras antagonist FPT inhibitor III (1 µM), the Raf inhibitor ZM 336372 (1 µM), and the MEK1 inhibitor PD98059 (20 µM), respectively (n = 3) (Fig. 11B). The ROS-mediated down-regulation of Pgp by BSO treatment was completely abolished upon inhibition of the Ras-mediated tyrosine kinase signaling pathway, which clearly indicates that EGF-mediated signal transduction pathways are negatively regulating Pgp expression. None of the applied antagonists of receptor tyrosine kinase pathways exerted significant effects on intracellular ROS levels (data not shown).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 11.   Regulation of Pgp expression in multicellular DU-145 tumor spheroids by receptor tyrosine kinase pathways. A, effects of tyrphostin AG 1478 (10 µM), which selectively inhibits EGF receptor kinase, serum-free conditions, and different concentrations of EGF on the expression of Pgp in large, non-necrotic tumor spheroids (diameter 300 ± 50 µm, day 14 of tumor spheroid culture). After 24 h of incubation the tumor spheroids were fixed and Pgp expression was quantified by immunohistochemistry. The data represent the relative Pgp immunofluorescence (%) in relation to the Pgp immunofluorescence obtained under serum-free conditions (set to 100%). Note, that the down-regulation of Pgp by EGF was totally abolished upon coadministration of the free radical scavenger ebselen. *, p < 0.05, significantly different from serum-free conditions. B, effects of antagonists of receptor tyrosine kinase pathways on the down-regulation of Pgp by BSO. Note, that all applied antagonists of receptor tyrosine kinase pathways totally abolished the BSO-mediated down-regulation of Pgp. *, p < 0.05, significantly different from the untreated control.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The present study reports on the correlation of endogenous intracellular ROS levels and the intrinsic expression of Pgp in multicellular prostate tumor spheroids of different size classes. The transient expression of Pgp during the growth of tumor spheroids, and its correlation with cell quiescence is apparently a general feature of tumor tissues, because tumor spheroids cultivated from glioma, melanoma, and hepatoma tumor cells displayed comparable features of intrinsic expression of Pgp as observed in the DU-145 prostate cancer cell line. The observation of a transient increase of Pgp-mediated drug resistance during the growth of avascular micrometastases may be of clinical significance, because the outcome of chemotherapeutic treatment critically depends on the chemosensitivity of the treated neoplastic tissue, which may be predicted from levels of Pgp expression as well as the expression of cell cycle-related genes in tumor biopsies. In DU-145 tumor spheroids the intrinsic Pgp expression was clearly correlated to increased levels of the CDK inhibitors p27Kip1 and p21WAF-1, which are increased during cell cycle arrest. Consequently, tumor spheroids with elevated levels of Pgp expression displayed minor endogenous activity of the cell growth-associated MAPK-members ERK1,2 and JNK. There is increasing evidence that the growth of neoplastic tissues is controlled by the generation of ROS, which have been previously shown to arise in Ras-mediated signaling pathways (23). The data of the present study are in notion with these previous studies, because it is demonstrated that increased ROS generation was observed in small tumor spheroids that consist predominantly of exponentially growing Ki-67-positive cells as well as in large tumor spheroids containing extended central necrosis. The increase in Ki-67 expression was paralleled by an augmented activity of JNK in small spheroids and large spheroids containing central necrosis as well as an increased activity of ERK1,2 in small tumor spheroids.

The correlation of elevated Pgp levels with reduced levels of ROS as well as diminished activity of ERK1,2 and JNK led us to hypothesize that raising intracellular ROS may down-regulate Pgp expression via up-regulation of ERK1,2 and JNK. An increase in intracellular ROS was achieved by: addition of hydrogen peroxide to the cell culture medium, depletion of intracellular glutathione by the use of BSO and glutamine-reduced cell culture medium, as well as treatment with EGF, which has been previously demonstrated to raise intracellular ROS (31). All these experimental procedures resulted in significant down-regulation of Pgp levels, indicating that ROS are involved in the signaling pathways that regulate the expression of Pgp. Interestingly, with hydrogen peroxide concentrations exceeding 500 µM an up-regulation of Pgp was observed. A rise in Pgp expression following treatment of cells with hydrogen peroxide has been previously demonstrated (15). In this study millimolar concentrations of H2O2 were administered, resulting in a parallel up-regulation of poly-(ADP-ribose) polymerase, which is a nuclear enzyme induced by DNA strand breaks. Furthermore, stress-induced expression of Pgp has been recently evidenced under various conditions, i.e. UV radiation (32), low external pH and osmotic shock (33) as well as heat stress (34). Most of these stress factors are accompanied by the generation of intracellular ROS. Under stress conditions the physiological role of Pgp may be related to the prevention of apoptosis (35), presumably by regulating caspase-dependent apoptotic pathways (36). This notion is furthermore supported by studies that demonstrated that overexpression of Pgp is correlated with increased levels of the anti-apoptotic Bcl-xL protein (37). ROS acting as signaling agents in the regulation of cell proliferation are in the nanomolar to micromolar range and are therefore significantly lower than the concentrations necessary to induce DNA strand breakage (38). Hence, intracellular ROS may exert differential effects on the regulation of MDR-related genes, which are dependent on their intracellular concentration.

In the present study raising intracellular ROS by depletion of glutathione resulted in a decline of p27Kip1 expression, whereas activity of ERK1,2 and JNK was significantly elevated, which indicates that in parallel to the down-regulation of Pgp expression a stimulation of the cell cycle was achieved, suggesting that cell cycle stimulation by ROS and the regulation of Pgp expression may share a common signal transduction pathway. This assumption was supported by experiments demonstrating that pharmacological inhibition of members of the receptor tyrosine kinase pathway utilized by EGF, and involving PKC and Ras/Raf as well as ERK1,2, abolished the observed down-regulation of Pgp following elevation of intracellular ROS. Interestingly, incubation of tumor spheroids in serum-free media and treatment with tyrphostin, which inhibits protein tyrosine kinases, including autophosphorylation of EGF receptor kinase, significantly increased the expression of Pgp in multicellular tumor spheroids. These findings support the notion that EGF present in the fetal calf serum used in the cell culture medium and/or EGF secreted by tumor cells may regulate Pgp expression via the activation of receptor tyrosine kinase signaling pathways.

The apparent effects of ROS on Pgp expression levels and cell cycle activity in multicellular tumor spheroids may be clinically utilized in anti-cancer trials. In EMT-6 tumor spheroids down-regulation of p27Kip1, which has been discussed as a regulator of MDR (39), by antisense nucleotides increased cell proliferation and sensitized tumor cells to 4-hydroperoxycyclophosphamide (39). A comparable chemosensitization in EMT-6 tumor spheroids was observed by treatment with hyaluronidase, which reduced intercellular communication and activated cell proliferation (40). Furthermore, stimulation of cell proliferation in noncycling hematopoietic progenitor cells and leukemic blasts resulted in a down-regulation of Pgp-mediated MDR (41). An elevation of ROS by depletion of intracellular glutathione sounds reasonable, because BSO has successfully been applied in vivo in cancer patients and was shown to increase the sensitivity of cancer cells toward antineoplastic drugs (42). Because most antineoplastic agents are acting against rapidly cycling cancer cells, the concomitant cell cycle stimulation and down-regulation of Pgp by ROS may offer new avenues for conventional chemotherapy. This may hold especially true for hormone-independent metastatic prostate tumors, which are characterized by a high fraction of cells resting in the G0 phase of the cell cycle and a pronounced intrinsic resistance to a broad range of anti-cancer agents (9).

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Neurophysiology, University of Cologne, Robert-Koch-Strasse 39, D-50931 Cologne, Germany. Tel.: 49-221-478 6976; Fax: 49-221-344527; E-mail: hs@physiologie.uni-koeln.de.

Published, JBC Papers in Press, February 20, 2001, DOI 10.1074/jbc.M100141200

    ABBREVIATIONS

The abbreviations used are: Pgp, P-glycoprotein; MDR, multidrug resistance; ROS, reactive oxygen species; MAPK, mitogen-activated protein kinase; BSO, buthionine sulfoximine; EGF, epidermal growth factor; FPT inhibitor III, farnesyl protein transferase inhibitor III; ZM 336372, N-[5-(3-dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; BIM-1, bisindolylmaleimide I; Ro-31-8220, bisindolylmaleimide IX; PD98059, 2'amino-3'-methoxyflavone; DCF, 2',7'-dichlorofluorescein; H2DCFDA, 2',7'-dichlorodihydrofluorescein diacetate; PBS, phosphate-buffered saline; PBST, PBS supplemented with 1% Triton X-100; H2DCF, 2',7'-dichlorodihydrofluorescein; RT-PCR, reverse transcriptase-polymerase chain reaction; ERK, extracellular signal-regulated kinase; bp, base pair(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Gottesman, M. M., and Pastan, I. (1993) Annu. Rev. Biochem. 62, 385-427[CrossRef][Medline] [Order article via Infotrieve]
2. Simon, S. M., and Schindler, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3497-3504[Abstract]
3. Volm, M. (1998) Anticancer Res. 18, 2905-2917[Medline] [Order article via Infotrieve]
4. Oda, Y., Schneider-Stock, R., Rys, J., Gruchala, A., Niezabitowski, A., and Roessner, A. (1996) Diagn. Mol. Pathol. 5, 98-106[CrossRef][Medline] [Order article via Infotrieve]
5. Dhar, D. K., Nagasue, N., Yoshimura, H., Tachibana, M., Tahara, H., Matsuura, H., Abe, S., Chang, Y. C., and Nakamura, T. (1995) J. Surg. Oncol. 60, 50-54[Medline] [Order article via Infotrieve]
6. Pilarski, L. M., and Belch, A. R. (1995) Leuk. Lymphoma 17, 367-374[Medline] [Order article via Infotrieve]
7. Wartenberg, M., Frey, C., Diedershagen, H., Ritgen, J., Hescheler, J., and Sauer, H. (1998) Int. J. Cancer 75, 855-863[CrossRef][Medline] [Order article via Infotrieve]
8. Wartenberg, M., Hescheler, J., Acker, H., Diedershagen, H., and Sauer, H. (1998) Cytometry 31, 137-145[CrossRef][Medline] [Order article via Infotrieve]
9. Naito, S., Yokomizo, A., and Koga, H. (1999) Int. J. Urol. 6, 427-439[CrossRef][Medline] [Order article via Infotrieve]
10. Beedassy, A., and Cardi, G. (1999) Semin. Oncol. 26, 428-438[Medline] [Order article via Infotrieve]
11. Sarkadi, B., and Muller, M. (1997) Semin. Cancer Biol. 8, 171-182[CrossRef][Medline] [Order article via Infotrieve]
12. Stein, U., Walther, W., Laurencot, C. M., Scheffer, G. L., Scheper, R. J., and Shoemaker, R. H. (1997) J. Natl. Cancer Inst. 89, 807-813[Abstract/Free Full Text]
13. Deshpande, S. S., Angkeow, P., Huang, J., Ozaki, M., and Irani, K. (2000) FASEB J. 14, 1705-1714[Abstract/Free Full Text]
14. Yamane, Y., Furuichi, M., Song, R., Van, N. T., Mulcahy, R. T., Ishikawa, T., and Kuo, M. T. (1998) J. Biol. Chem. 273, 31075-31085[Abstract/Free Full Text]
15. Ziemann, C., Burkle, A., Kahl, G. F., and Hirsch-Ernst, K. I. (1999) Carcinogenesis 20, 407-414[Abstract/Free Full Text]
16. Wartenberg, M., Fischer, K., Hescheler, J., and Sauer, H. (2000) Int. J. Cancer 85, 267-274[CrossRef][Medline] [Order article via Infotrieve]
17. Frenkel, K., and Gleichauf, C. (1991) Free Radic. Res. Commun. 12-13, 783-794
18. Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., and Von Hoff, D. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7160-7164[Abstract]
19. Wartenberg, M., and Acker, H. (1996) Anticancer Res. 16, 573-579[Medline] [Order article via Infotrieve]
20. Sauer, H., Hescheler, J., Reis, D., Diedershagen, H., Niedermeier, W., and Wartenberg, M. (1997) Br. J. Cancer 75, 1481-1488[Medline] [Order article via Infotrieve]
21. Szatrowski, T. P., and Nathan, C. F. (1991) Cancer Res. 51, 794-798[Abstract]
22. Burdon, R. H. (1996) Biochem. Soc. Trans. 24, 1028-1032[Medline] [Order article via Infotrieve]
23. Irani, K., Xia, Y., Zweier, J. L., Sollott, S. J., Der, C. J., Fearon, E. R., Sundaresan, M., Finkel, T., and Goldschmidt-Clermont, P. J. (1997) Science 275, 1649-1652[Abstract/Free Full Text]
24. Wartenberg, M., Hescheler, J., and Sauer, H. (1997) Am. J. Physiol. 272, R1677-R1683[Abstract/Free Full Text]
25. Griffith, O. W., and Meister, A. (1979) J. Biol. Chem. 254, 7558-7560[Abstract]
26. Dringen, R., and Hamprecht, B. (1996) J. Neurochem. 67, 1375-1382[Medline] [Order article via Infotrieve]
27. Maiorino, M., Roveri, A., and Ursini, F. (1992) Arch. Biochem. Biophys. 295, 404-409[Medline] [Order article via Infotrieve]
28. Sauer, H., Diedershagen, H., Hescheler, J., and Wartenberg, M. (1997) FEBS Lett. 419, 201-205[CrossRef][Medline] [Order article via Infotrieve]
29. Wartenberg, M., Diedershagen, H., Hescheler, J., and Sauer, H. (1999) J. Biol. Chem. 274, 27759-27767[Abstract/Free Full Text]
30. Bae, G. U., Seo, D. W., Kwon, H. K., Lee, H. Y., Hong, S., Lee, Z. W., Ha, K. S., Lee, H. W., and Han, J. W. (1999) J. Biol. Chem. 274, 32596-32602[Abstract/Free Full Text]
31. Bae, Y. S., Kang, S. W., Seo, M. S., Baines, I. C., Tekle, E., Chock, P. B., and Rhee, S. G. (1997) J. Biol. Chem. 272, 217-221[Abstract/Free Full Text]
32. Uchiumi, T., Kohno, K., Tanimura, H., Matsuo, K., Sato, S., Uchida, Y., and Kuwano, M. (1993) Cell Growth & Differ. 4, 147-157[Abstract]
33. Wei, L. Y., and Roepe, P. D. (1994) Biochemistry 33, 7229-7238[Medline] [Order article via Infotrieve]
34. Miyazaki, M., Kohno, K., Uchiumi, T., Tanimura, H., Matsuo, K., Nasu, M., and Kuwano, M. (1992) Biochem. Biophys. Res. Commun. 187, 677-684[Medline] [Order article via Infotrieve]
35. Johnstone, R. W., Cretney, E., and Smyth, M. J. (1999) Blood 93, 1075-1085[Abstract/Free Full Text]
36. Smyth, M. J., Krasovskis, E., Sutton, V. R., and Johnstone, R. W. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7024-7029[Abstract/Free Full Text]
37. Kojima, H., Endo, K., Moriyama, H., Tanaka, Y., Alnemri, E. S., Slapak, C. A., Teicher, B., Kufe, D., and Datta, R. (1998) J. Biol. Chem. 273, 16647-16650[Abstract/Free Full Text]
38. Burdon, R. H., Gill, V., and Alliangana, D. (1996) Free Radic. Res. 24, 81-93[Medline] [Order article via Infotrieve]
39. St. Croix, B., Florenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., and Kerbel, R. S. (1996) Nat. Med. 2, 1204-1210[Medline] [Order article via Infotrieve]
40. Croix, B. S., Rak, J. W., Kapitain, S., Sheehan, C., Graham, C. H., and Kerbel, R. S. (1996) J. Natl. Cancer Inst. 88, 1285-1296[Abstract/Free Full Text]
41. Smeets, M. E., Raymakers, R. A., Vierwinden, G., Pennings, A. H., Wessels, H., and de Witte, T. (1999) Blood 94, 2414-2423[Abstract/Free Full Text]
42. O'Dwyer, P. J., Hamilton, T. C., LaCreta, F. P., Gallo, J. M., Kilpatrick, D., Halbherr, T., Brennan, J., Bookman, M. A., Hoffman, J., Young, R. C., Comis, R. L., and Ozols, R. F. (1996) J. Clin. Oncol. 14, 249-256[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.